The purpose is to assess whether the test product and the branded product are bioequivalence, meaning they provide the same amount of medicine to the body. Participants will take one of the liquid preparations after a regular meal, then, after a short interval, will take the other preparation after another meal. Blood samples will be collected to compare how the two products are absorbed, without further technical detail.

The purpose of this study is to find out if trimodulin is effective and safe when added to standard care for treating hospitalized adult patients with community-acquired pneumonia or COVID-19 pneumonia. The study will look at whether patients who receive trimodulin do better than those who receive placebo by measuring how many patients get worse or die during the study period. Patients in the study will receive the treatment through an infusion into a vein over five days.

During the study, doctors will monitor patients for up to 91 days to see how they respond to treatment. They will check if patients need more intensive breathing support or if their condition improves, stays the same, or gets worse. The study will also measure various blood markers related to inflammation, immune system function, and blood clotting to understand how the treatment works in the body. Safety will be carefully watched by recording any unwanted effects that occur during and after the treatment period.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

The purpose of this study is to learn more about how these medications work in the body, as well as to check their safety and how well they are tolerated by the infants. The study will be conducted in two parts, where the infants will receive either a single dose or multiple doses of the medications. The medications will be given through an intravenous infusion, which means they will be delivered directly into the bloodstream through a vein. The study will monitor the infants closely to see how their bodies process the medications and to watch for any side effects or reactions.

Throughout the study, researchers will collect information on how the medications affect the infants’ infections and overall health. This includes checking the levels of the medications in the blood, observing any side effects, and assessing the infants’ recovery from the infections. The study aims to provide valuable information that could help improve the treatment of serious bacterial infections in very young children.

The purpose of the study is to determine if a shorter, high-dose treatment is as effective as the traditional longer treatment in terms of patient survival over 90 days. The study will involve patients who are in the intensive care unit (ICU) and are expected to stay there for a certain period. During the trial, some patients will receive the short course, high-dose treatment, while others will receive the conventional treatment. The study will monitor various outcomes, including survival rates, the occurrence of new infections, and the overall health and recovery of the patients.

Participants in the study will be closely monitored for any side effects or complications. The trial aims to find out if the shorter treatment can reduce the exposure to antibiotics without compromising the effectiveness of the treatment. This could potentially lead to better management of antibiotic use in critically ill patients, helping to prevent the development of antibiotic resistance and improve patient outcomes.

Participants in the study will receive either amoxicillin or a placebo. The treatment will be administered as an oral suspension, which is a liquid form taken by mouth. The study will monitor the children’s health over a period of time to see how well the treatment works. Researchers will look at various factors, such as the duration of fever and symptoms, and whether there is a need for additional antibiotic treatment.

The study aims to provide valuable information on the effectiveness of amoxicillin in treating pneumonia in young children. By comparing the outcomes of those receiving the antibiotic to those receiving a placebo, researchers hope to better understand the role of amoxicillin in managing this common childhood illness.

The treatment involves giving patients either aspirin or placebo. The aspirin will be given in different forms: as a gastro-resistant tablet, as an intravenous solution, or with sodium chloride solution. The medication or placebo will be given over a period of 90 days while monitoring the patient’s condition.

The study will track how many patients survive and what complications they experience, particularly focusing on heart and blood vessel-related problems. Researchers will also monitor for any bleeding that might occur as a side effect of the treatment. The study will follow patients for up to 120 days to understand both the benefits and risks of using aspirin in elderly pneumonia patients.

In this study, children aged between 3 months and 59 months who have been diagnosed with community-acquired pneumonia will receive amoxicillin trihydrate. The treatment will be given in two different ways: one group will receive the antibiotic for 3 days if they respond quickly to the treatment, or for 5 days if their response is slower. The other group will receive the antibiotic for 5 days if they respond quickly, or for 7 days if their response is slower. The study aims to find out if the shorter treatment is as effective as the longer one in preventing treatment failure, which means the treatment does not work as expected.

The study will monitor the children for any signs of treatment failure, such as the need to change the antibiotic, worsening of pneumonia, or the need for hospitalization. It will also look at any side effects from the antibiotic and how well the children follow the treatment plan. The study will help determine the best duration for antibiotic treatment in children with community-acquired pneumonia, aiming to reduce unnecessary antibiotic use while ensuring effective treatment.

The purpose of the study is to explore whether a specific approach to managing VAP, which includes daily checks to see if the infection has been cured and stopping the antibiotics if it has, is as effective as the usual treatment methods. Participants in the study will receive either the treatment with amoxicillin and clavulanic acid or a placebo. The study will monitor the participants over a period of time to observe outcomes such as survival rates, the recurrence of pneumonia, and any new episodes of VAP.

Throughout the study, researchers will also look at other factors, such as the number of days patients are free from antibiotics, the length of stay in the intensive care unit, and any side effects from the antibiotics. The study aims to provide valuable insights into the best ways to treat VAP in patients who are critically ill and require mechanical ventilation.

The treatment involves taking oral antibiotics, and patients will be monitored using connected devices to evaluate their response to the medication. The study will track how quickly patients recover from their pneumonia symptoms and measure the effectiveness of different antibiotic treatment durations. The treatment period may last between 5 to 14 days, depending on the specific antibiotic used and the patient’s response to treatment.

Throughout the study, researchers will monitor patients’ recovery for up to 30 days after starting treatment. They will assess various factors including the improvement of pneumonia symptoms, any side effects from the antibiotics, and the overall effectiveness of the individualized treatment approach. The study will also examine how different antibiotics affect the natural bacteria in the respiratory system and gut.

The purpose of the study is to find out how effective dexamethasone phosphate is when used alongside the usual care that patients receive, compared to a placebo, which is a substance with no active medication. The study will involve patients receiving either the medication or the placebo, and their progress will be monitored over a period of time. The treatment with the medication or placebo will last for up to five days, and the patients’ health will be checked regularly to see how they are responding to the treatment.

Throughout the study, researchers will look at various outcomes, such as whether the pneumonia is cured and the overall survival of the patients after 28 days. They will also monitor for any side effects or complications that might occur during the treatment period. The study aims to provide valuable information on whether dexamethasone phosphate can be a beneficial addition to the standard care for patients with severe hospital-acquired pneumonia.

The purpose of the study is to provide reliable estimates of how these treatments affect the chances of survival and the time it takes for patients to be discharged from the hospital. Participants in the study will receive one of the medications or a placebo, and their progress will be monitored over a period of time. The study aims to understand which treatments are most effective in helping patients recover from pneumonia.

During the study, patients will be given the medication in different forms, such as capsules, tablets, or injections, depending on the specific treatment. The study will last for a maximum of 10 days for each participant, and their health will be closely observed to gather information on the effectiveness of the treatments. The results will help doctors make better decisions about how to treat pneumonia in the future.

The purpose of the study is to assess the safety and tolerability of AON-D21 in patients with severe pneumonia who are admitted to an intensive care unit. Participants in the study will receive either the AON-D21 treatment or a placebo, which is a solution that does not contain the active medication. The study will follow participants over a period of time to monitor their response to the treatment and any side effects they may experience.

Throughout the study, researchers will observe how long it takes for patients to no longer need respiratory support, which includes various forms of oxygen therapy and mechanical ventilation. They will also track the number of days patients are free from needing organ support and any changes in their condition over time. The study aims to provide valuable information on the potential benefits and risks of using AON-D21 as an additional treatment for severe pneumonia.

The purpose of the study is to evaluate the effectiveness and safety of TAD® as an additional treatment to prevent heart damage in patients hospitalized with pneumonia. Participants in the study will receive the treatment intravenously, meaning it will be administered directly into a vein. The study will compare the effects of TAD® with those of a placebo to determine its potential benefits. The trial will be conducted over a period of several days, during which participants will be closely monitored for any changes in their heart health.

Throughout the study, various health assessments will be conducted to monitor the participants’ heart function and overall well-being. These assessments will include measuring levels of certain proteins in the blood that indicate heart health, as well as performing tests like electrocardiograms (ECGs) to check heart rhythm and function. The study aims to provide valuable information on whether TAD® can be a safe and effective option for preventing heart damage in patients with pneumonia.

The purpose of the study is to evaluate the safety and tolerability of TP-122A when given to patients with ventilator-associated pneumonia. Participants in the study will receive multiple doses of TP-122A through inhalation every 8 hours for 7 days. The study will compare the effects of TP-122A combined with standard care to standard care alone. Throughout the study, researchers will monitor participants for any side effects and changes in their health, including vital signs and laboratory tests.

The study aims to understand how well TP-122A is tolerated by patients and whether it can help improve their condition. Researchers will also look at how quickly patients recover from the infection and how long they need to stay on a ventilator or in the intensive care unit. The ultimate goal is to find out if TP-122A can be a safe and effective treatment option for people with ventilator-associated pneumonia.

The purpose of the study is to determine how well the Apexxnar vaccine works in preventing pneumonia caused by specific types of bacteria that the vaccine targets. Participants in the study will receive either the vaccine or a placebo. The study will monitor participants to see if they develop pneumonia and will use this information to assess the vaccine’s effectiveness. The vaccine is given as an injection into the muscle, similar to a flu shot.

Throughout the study, participants will be observed for any signs of pneumonia, such as fever, cough, or difficulty breathing. The study will also consider factors like age, sex, and previous vaccinations to understand how these might affect the vaccine’s performance. The trial is expected to continue until 2027, providing valuable data on the vaccine’s ability to prevent pneumonia in older adults.

Participants in the study will receive either the ALIS treatment combined with azithromycin and ethambutol or a placebo, which is a substance with no active medication, combined with azithromycin and ethambutol. The study will last for about 13 months, during which time participants will be monitored for changes in their respiratory symptoms and overall health. The study aims to see if the ALIS-based treatment can help reduce symptoms and improve the quality of life for those with this lung infection.

Throughout the study, participants will have regular check-ups and tests to assess their health and the effectiveness of the treatment. These tests may include providing sputum samples, which are samples of mucus from the lungs, and undergoing imaging tests like computed tomography (CT) scans to look at the lungs. The study will also track any side effects or changes in symptoms to ensure the safety and well-being of the participants.

The purpose of this study is to determine if adding inhaled levofloxacin to the treatment plan for patients with community-acquired pneumonia, including those with pre-existing lung conditions, improves or worsens their health status. Participants will receive the treatment twice daily for three days. The study will monitor changes in the participants’ health, such as breathing ability and infection levels, to assess the effectiveness of the treatment.

Throughout the study, participants will be observed for any changes in their condition, including symptoms like fever, cough, and difficulty breathing. The trial aims to gather information on how well the treatment works and its impact on patients’ recovery from pneumonia. This information will help in understanding the potential benefits and risks of using inhaled levofloxacin for treating community-acquired pneumonia.

The purpose of the study is to determine if the inhaled levofloxacin treatment is as effective as the intravenous piperacillin/tazobactam treatment in helping patients recover from pneumonia. Participants in the study will receive one of these treatments for 4 to 5 days. The study will monitor how many days patients are alive and out of the hospital within 14 days after starting treatment. This will help researchers understand which treatment allows patients to recover more quickly and safely.

Throughout the study, researchers will also look at other factors, such as any side effects from the antibiotics, changes in the diversity of bacteria in the gut, and overall health outcomes at 30 days. This information will help provide a clearer picture of the benefits and risks of each treatment option for community-acquired pneumonia.

Participants in the study will receive either aspirin or a placebo, which looks like the aspirin tablet but does not contain any active medication. The study will also involve another medication called pantoprazole, which is used to protect the stomach lining. The treatment period will last for up to 90 days, and the researchers will monitor the participants’ health for any heart-related events and other outcomes over a period of 180 days.

The goal of this study is to determine if aspirin can provide additional benefits in preventing heart-related complications in patients with pneumonia. By understanding the potential benefits of aspirin in this context, the study hopes to improve treatment strategies for patients with pneumonia who are at risk of heart problems. Participants will be closely monitored throughout the study to ensure their safety and well-being.

Participants in the study will receive ceftriaxone either every 24 hours or every 12 hours, depending on their risk for a condition called augmented renal clearance (ARC). ARC is when the kidneys clear drugs from the body faster than usual, which can affect how well the medication works. The study will monitor various outcomes, such as the length of stay in the intensive care unit (ICU), survival rates, and the effectiveness of the treatment in clearing the infection.

The study will also look at other factors, such as the number of days patients are free from needing a ventilator, the presence of any side effects, and changes in certain blood markers that indicate infection. The trial aims to provide valuable information on how to best use ceftriaxone to treat severe community-acquired pneumonia in critically ill patients.

Participants in the study will receive one of the antibiotics mentioned above, or a placebo, for a period of up to 10 days. The study will monitor patients to determine when it is safe to stop the antibiotic treatment based on specific health criteria, such as body temperature and heart rate. The goal is to see if stopping antibiotics when these criteria are met is as effective as the traditional longer treatment duration.

The trial will track the patients’ recovery over a period of 30 days, checking for the persistence of stability criteria, the need for additional antibiotic treatment, and overall health outcomes. The study will also assess the impact of the treatment on the patients’ quality of life and any side effects experienced during the trial period. This research aims to improve the management of community-acquired pneumonia by potentially reducing the duration of antibiotic use without compromising patient recovery.

The purpose of the study is to determine if the treatment with amoxicillin alone is as effective as the combination treatment in terms of clinical success. Clinical success is defined as the patient surviving after completing the antibiotic treatment, with the resolution of symptoms such as cough, difficulty breathing, and chest pain, and no new symptoms or complications related to the pneumonia. The study will follow patients for 30 days after they are admitted to the hospital to assess the effectiveness of the treatments.

Participants in the study will receive either the amoxicillin alone or the combination of amoxicillin and clavulanic acid for a maximum of five days. The study will monitor various outcomes, including the improvement of symptoms, the need for additional antibiotics, and overall survival. The study aims to provide valuable information on the best treatment approach for older adults with community-acquired pneumonia who are hospitalized in non-intensive care settings.

The purpose of the study is to evaluate the pharmacokinetics (PK) – how the medicine moves through the body – as well as safety and how well it is tolerated. Children will be treated for a short period, with blood samples taken to check drug levels and regular checks of liver and kidney function. After the treatment ends, follow‑up visits will assess whether the infection has cleared and whether any side effects occurred.

The purpose of the study is to evaluate the safety and tolerability of this treatment in children who have been diagnosed with nosocomial pneumonia. Participants in the study will receive the medication and be monitored for any side effects or reactions. The study will also measure how the body processes the medication, including how it is absorbed, distributed, and eliminated. This information will help determine the appropriate dosage and frequency for treating this type of pneumonia in pediatric patients.

Throughout the study, researchers will collect data on the participants’ health and any adverse events they may experience. This will help ensure that the treatment is safe and effective for children with nosocomial pneumonia. The study is designed to provide valuable insights into the use of ceftolozane and tazobactam in treating this serious infection in a hospital setting.

Participants in the study will receive either the recombinant human interferon gamma 1b or a placebo, which is a substance with no active medication. The study will monitor how long patients remain on mechanical ventilation and other factors such as the length of stay in the ICU and hospital, the occurrence of any additional episodes of pneumonia, and overall survival rates in the ICU. The study will also look at how the treatment affects certain immune system markers in the blood.

The trial will last for a period of time during which patients will be closely observed to gather data on the effectiveness and safety of the treatment. The goal is to determine if recombinant human interferon gamma 1b can provide a significant benefit in treating ventilator-acquired pneumonia in ICU patients. This research could potentially lead to improved treatment options for patients suffering from this serious condition.

The purpose of the study is to see if Trimodulin can reduce the number of deaths within 28 days compared to the placebo. Participants in the study are adults who are hospitalized with severe pneumonia. The study will follow these patients over a period of time to monitor their health and recovery. Researchers will look at various outcomes, such as how many patients survive, how their health changes over time, and how long they need to stay in the hospital or intensive care unit.

Throughout the study, doctors will also check for any side effects or reactions to the treatment. The study aims to provide valuable information on whether Trimodulin is a safe and effective treatment for severe pneumonia, potentially offering a new option for patients with this serious condition.

The purpose of the study is to evaluate how well CAL02 works and how safe it is compared to a placebo. Participants in the study will receive either CAL02 or a placebo, in addition to the standard treatments they would normally receive for their condition. The study will monitor how quickly patients recover from the pneumonia and any side effects they might experience from the treatment. The treatment period lasts for a maximum of two days, and the study will track the participants’ progress over time to gather information on their recovery and any potential side effects.

By participating in this study, researchers hope to learn more about the potential benefits of CAL02 for treating severe community-acquired bacterial pneumonia. The information gathered will help determine if CAL02 can be a safe and effective addition to the current standard of care for this serious lung infection.

The purpose of the study is to determine if adding baricitinib to the standard treatment is safe and effective for patients with hospital-acquired pneumonia. Participants in the study will receive either baricitinib or a placebo, along with the standard care they would normally receive. The study will take place over a period of time, and participants will be monitored to see how well they respond to the treatment and to check for any side effects.

Throughout the study, researchers will look at various outcomes, such as whether the treatment helps cure the pneumonia and if it affects the overall health and quality of life of the patients. The study will also assess the economic impact of using baricitinib in treating pneumonia. The results will help determine if baricitinib can be a beneficial addition to the treatment of hospital-acquired pneumonia in critically ill patients.

The purpose of the study is to determine if Co-trimoxazole is as effective as the best standard treatments currently available for treating VAP. Participants in the study will receive either Co-trimoxazole or another standard treatment, which may include medications like Temocillin, Piperacillin Sodium, Ciprofloxacin, Levofloxacin, Cefotaxime, Ofloxacin, Piperacillin, Ceftriaxone, Imipenem Monohydrate, Amoxicillin Sodium, Aztreonam, Ertapenem, Meropenem, or Cefepime. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

The study will last for a period of up to six weeks, during which participants will be closely monitored. The main focus will be on the participants’ health status 28 days after starting the treatment. Additional observations will include the number of days participants are free from mechanical ventilation, the length of stay in the ICU and hospital, and any side effects or allergic reactions to the medications. The study aims to provide valuable information on the safety and effectiveness of Co-trimoxazole as a treatment for VAP in intensive care settings.